Latest Insider Transactions at Cano Health, Inc. (CANO)
This section provides a real-time view of insider transactions for Cano Health, Inc. (CANO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cano Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cano Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2023
|
Jacqueline Guichelaar Director |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Angel L Morales |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Alan Muney |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Kim M Rivera |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Solomon D Trujillo |
BUY
Grant, award, or other acquisition
|
Direct |
211,581
+35.87%
|
-
|
|
Jun 12
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
500,000
-29.17%
|
$500,000
$1.42 P/Share
|
|
Jun 09
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-5.51%
|
$100,000
$1.38 P/Share
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
275,940
-13.2%
|
$275,940
$1.29 P/Share
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Bona fide gift
|
Direct |
600,000
+22.31%
|
-
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Bona fide gift
|
Indirect |
600,000
-100.0%
|
-
|
|
Jun 07
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
400,000
-21.16%
|
$400,000
$1.32 P/Share
|
|
Jun 06
2023
|
David J Armstrong |
SELL
Open market or private sale
|
Direct |
3,163
-0.48%
|
$3,163
$1.38 P/Share
|
|
May 31
2023
|
Mark Novell Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,502
+20.68%
|
-
|
|
May 31
2023
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
109,526
+14.24%
|
-
|
|
May 31
2023
|
Marlow Hernandez |
BUY
Grant, award, or other acquisition
|
Direct |
671,742
+12.5%
|
-
|
|
May 31
2023
|
Brian D Koppy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
248,226
+19.11%
|
-
|
|
May 31
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
231,008
+15.99%
|
-
|
|
May 31
2023
|
Robert Camerlinck Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
239,139
+0.88%
|
-
|
|
May 25
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Conversion of derivative security
|
Indirect |
600,000
+50.0%
|
-
|
|
May 25
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Conversion of derivative security
|
Direct |
675,940
+26.34%
|
-
|
|
Apr 11
2023
|
Mark Novell Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,684
+23.15%
|
-
|
|
Apr 05
2023
|
Robert Camerlinck Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
2,836,540
+9.59%
|
-
|
|
Apr 05
2023
|
Brian D Koppy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,591
-2.86%
|
$23,591
$1.27 P/Share
|
|
Mar 31
2023
|
David J Armstrong |
BUY
Conversion of derivative security
|
Direct |
185,000
+18.02%
|
-
|
|
Mar 31
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,116
+10.89%
|
-
|
|
Mar 31
2023
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
70,108
+11.3%
|
-
|
|
Mar 31
2023
|
Brian D Koppy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
124,206
+13.07%
|
-
|
|
Mar 31
2023
|
Robert Camerlinck Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,486
+0.29%
|
-
|
|
Mar 31
2023
|
Marlow Hernandez |
BUY
Grant, award, or other acquisition
|
Direct |
348,604
+7.96%
|
-
|
|
Jan 05
2023
|
Brian D Koppy Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,528
-3.91%
|
$28,528
$1.08 P/Share
|
|
Jan 05
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,010
-3.04%
|
$27,010
$1.08 P/Share
|
|
Jan 05
2023
|
Mark Novell Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,538
-3.65%
|
$4,538
$1.08 P/Share
|
|
Jan 05
2023
|
David J Armstrong |
SELL
Payment of exercise price or tax liability
|
Direct |
19,749
-3.95%
|
$19,749
$1.08 P/Share
|
|
Jan 03
2023
|
Marlow Hernandez |
BUY
Grant, award, or other acquisition
|
Direct |
134,660
+3.53%
|
$0
$0.87 P/Share
|
|
Jan 03
2023
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
13,006
+2.54%
|
$0
$0.87 P/Share
|
|
Sep 01
2022
|
Robert Camerlinck Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
25,386
+0.11%
|
-
|
|
Aug 31
2022
|
Brian D Koppy Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,651
-1.83%
|
$68,255
$5.95 P/Share
|
|
Aug 31
2022
|
Mark Novell Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,387
-5.6%
|
$36,935
$5.95 P/Share
|
|
Aug 31
2022
|
David J Armstrong |
SELL
Payment of exercise price or tax liability
|
Direct |
20,500
-4.04%
|
$102,500
$5.95 P/Share
|
|
Aug 10
2022
|
Robert Camerlinck Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+1.04%
|
-
|
|
Aug 10
2022
|
Mark Novell Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+15.4%
|
-
|
|
Jul 05
2022
|
Marlow Hernandez |
BUY
Grant, award, or other acquisition
|
Direct |
29,870
+0.84%
|
$89,610
$3.52 P/Share
|
|
Jul 05
2022
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
4,828
+0.94%
|
$14,484
$3.52 P/Share
|
|
Jun 07
2022
|
David J Armstrong |
SELL
Payment of exercise price or tax liability
|
Direct |
3,254
-0.64%
|
$16,270
$5.13 P/Share
|
|
May 26
2022
|
Marlow Hernandez |
BUY
Conversion of derivative security
|
Indirect |
11,017,311
+50.0%
|
-
|
|
May 16
2022
|
Kim M Rivera |
BUY
Grant, award, or other acquisition
|
Direct |
48,077
+43.32%
|
-
|
|
May 16
2022
|
Jacqueline Guichelaar Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,077
+43.32%
|
-
|
|
May 16
2022
|
Elliot Cooperstone |
BUY
Grant, award, or other acquisition
|
Direct |
48,077
+43.32%
|
-
|
|
May 16
2022
|
Angel L Morales |
BUY
Grant, award, or other acquisition
|
Direct |
48,077
+43.32%
|
-
|
|
May 16
2022
|
Alan Muney |
BUY
Grant, award, or other acquisition
|
Direct |
48,077
+43.32%
|
-
|